Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer

Background: Modified fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) regimen (mFOLFIRINOX), comprised of fluorouracil, leucovorin, irinotecan and oxaliplatin, is the first-line standard chemotherapy in patients with advanced pancreatic cancer. The S-1/oxaliplatin/irinotecan (SOXIRI) regimen has also been studied recently under similar conditions. This study compared its efficacy and safety. Methods: All cases of locally advanced or metastatic pancreatic cancer treated with the SOXIRI or mFOLFIRINOX regimen in Sun Yat-sen University Cancer Centre from July 2012 to June 2021 were reviewed retrospectively. The data of patients who satisfied the inclusion criteria were compared between two cohorts, including overall survival (OS), progression-free survival (PFS), objective response rate, disease control rate and safety. Results: A total of 198 patients were enrolled in the study, including 102 patients treated with SOXIRI and 96 patients treated with mFOLFIRINOX. There was no significant difference in OS [12.1 months versus 11.2 months, hazard ratio (HR) = 1.04, p = 0.81] or PFS (6.5 months versus 6.8 months, HR = 0.99, p = 0.96) between patients treated with SOXIRI and mFOLFIRINOX. In the subgroup analysis, patients with slightly elevated baseline total bilirubin (TBIL) or underweight patients before chemotherapy were more likely to have a longer OS or PFS from SOXIRI than from mFOLFIRINOX. In addition, the carbohydrate antigen (CA)19-9 decline was a good predictor for the efficacy and prognosis of both chemotherapy regimens. All grade adverse events were parallel in all kinds of toxicities except that anaemia was more common in the SOXIRI group than in the mFOLFIRINOX group (41.4% versus 24%, p = 0.03). The occurrence of any grade 3 to 4 toxicity was similar in the two groups. Conclusions: For locally advanced or metastatic pancreatic cancer patients, the SOXIRI regimen had similar efficacy and controllable safety compared with the mFOLFIRINOX regimen.

[1]  C. Telleria,et al.  Revisiting the Anti-Cancer Toxicity of Clinically Approved Platinating Derivatives , 2022, International journal of molecular sciences.

[2]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[3]  L. Ocuin,et al.  Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. , 2021, American journal of surgery.

[4]  Chengliang Zhang,et al.  Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. , 2021, Toxicology.

[5]  N. Sakamoto,et al.  A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403) , 2021, The oncologist.

[6]  Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. , 2021, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[7]  E. Nakakura,et al.  Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. , 2021, Journal of the National Comprehensive Cancer Network : JNCCN.

[8]  E. Greene.  Challenges in Reducing Infection Risks When Accessing Vascular Catheters. , 2021, The Journal of hospital infection.

[9]  Zhongfa Zhang,et al.  Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study , 2020, Therapeutic advances in medical oncology.

[10]  Y. Ba,et al.  The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer , 2019, Cancer communications.

[11]  A. Chan,et al.  Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer , 2019, Nutrition and cancer.

[12]  S. Satoi,et al.  Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S‐1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma , 2019, The oncologist.

[13]  J. Neoptolemos,et al.  Diagnosis and management of pancreatic cancer in adults: A summary of guidelines from the UK National Institute for Health and Care Excellence. , 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[14]  T. Conroy,et al.  Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). , 2018, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[15]  Qi Zhang,et al.  Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. , 2017, Cancer letters.

[16]  T. Conroy,et al.  Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4) , 2017, Oncology.

[17]  V. Gebski,et al.  First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials , 2017, The Lancet. Oncology.

[18]  T. Ohtsuka,et al.  Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis , 2017, Pancreas.

[19]  H. Ueno,et al.  Multicenter, randomized, open-label Phase II study comparing S-1 alternate-day oral therapy with the standard daily regimen as a first-line treatment in patients with unresectable advanced pancreatic cancer , 2017, Cancer Chemotherapy and Pharmacology.

[20]  N. Sata,et al.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) , 2016, The Lancet.

[21]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[22]  R. Salem,et al.  Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer , 2016, British Journal of Cancer.

[23]  M. Reni,et al.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Amy P Abernethy,et al.  Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). , 2015, JAMA oncology.

[25]  N. Staff,et al.  Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[27]  H. Ueno,et al.  Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Yamaue,et al.  S-1 as a core anticancer fluoropyrimidine agent , 2012, Expert opinion on drug delivery.

[29]  C. Liao,et al.  S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis , 2011, Medical oncology.

[30]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[31]  J. Roh,et al.  Copy number changes can be a predictor for hemoglobin reduction after S-1 monotherapy in gastric cancer. , 2009, International journal of oncology.

[32]  J. Ajani,et al.  Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  T. Rich,et al.  Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  G. Agnelli,et al.  Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Lehnert,et al.  Tumor treatment by sustained intratumoral release of 5-fluorouracil: effects of drug alone and in combined treatments. , 2002, International journal of radiation oncology, biology, physics.

[36]  Hiroshi Yamazaki,et al.  A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. , 2002, Pharmacogenetics.

[37]  E. Van Cutsem,et al.  Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  K. Sugimachi,et al.  Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma , 2000, British Journal of Cancer.

[39]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Uchida,et al.  Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats , 1996, Cancer Chemotherapy and Pharmacology.

[41]  M. Fukushima,et al.  Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. , 1993, Cancer research.

[42]  A. Schalhorn,et al.  Clinical pharmacokinetics of fluorouracil and folinic acid. , 1992, Seminars in oncology.

[43]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[44]  K. Tsuta,et al.  Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma , 2015, Cancer Chemotherapy and Pharmacology.

[45]  K. Sugimachi,et al.  Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. , 2000, British journal of cancer.

[46]  E. Warner,et al.  Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. Lokich,et al.  Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis. , 1996, Cancer.